Our findings thus highlight the potential of pharmaceutically targeting autophagy activity to boost not only CD4+ T cell (Figs. 4 and 5), but also CD8+ T-cell antiviral immunity in chronic HIV-1 infection. This evidence concerns the gene CD8A and HIV-1 infection.